Veradermics is also focused on bringing new value to patients and clinicians in the treatment of molluscum contagiosum. Molluscum is a poxvirus infection that affects six million Americans, results in one million doctors’ office visits annually in the U.S., and has no FDA-approved therapeutics. The company is developing VDMC as a first-in-class topical antiviral that was discovered by leading pox virus experts at the University of Pennsylvania and works against a specific molecular target. VDMC was designed to maximize safety for use in the pediatric population affected by molluscum.
Specifically, VDMC has anticipated minimal systemic absorption with topical application, is not expected to result in permanent scarring, and attacks a pox virus target that does not significantly overlap with human DNA synthesis machinery.
Viral Skin Infection
is a viral skin infection caused by a pox virus that primarily affects children
95% OF ALL CASES
OCCUR IN CHILDREN <14
are either ineffective,
or result in permanent side effects like scarring
Annual Doctors’ Visits
Source: 1. Fam Pract. 2014 Apr;31(2):130-6, 2. PLoS One. 2009;4(4):e5255, 3. IQVIA projected dataset for 12 months ending October 2017.